Transplacental Therapeutic Drug Monitoring in Pregnant Women with Fetal Tachyarrhythmia Using HPLC-MS/MS

Fetal arrhythmia develops in 0.1–5% of pregnancies and may cause fetal heart failure and fetal hydrops, thus increasing fetal, neonatal, and infant mortality. The timely initiation of transplacental antiarrhythmic therapy (ART) promotes the conversion of fetal tachycardia to sinus rhythm and the reg...

Descripción completa

Detalles Bibliográficos
Autores principales: Starodubtseva, Natalia, Kindysheva, Svetlana, Potapova, Alyona, Kukaev, Evgenii, Khodzhaeva, Zulfiya, Bockeria, Ekaterina, Chagovets, Vitaliy, Frankevich, Vladimir, Sukhikh, Gennady
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9916042/
https://www.ncbi.nlm.nih.gov/pubmed/36768172
http://dx.doi.org/10.3390/ijms24031848

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9916042/
https://www.ncbi.nlm.nih.gov/pubmed/36768172
http://dx.doi.org/10.3390/ijms24031848

Ejemplares similares